Benefits
Stress and anxiety symptom relief
A 6-week placebo-controlled trial of a tulsi extract in 150 adults with general stress reported about 39% greater reduction in self-rated stress symptoms (forgetfulness, exhaustion, sleep problems) versus placebo. A 60-day open-label trial in 35 people with generalized anxiety disorder reported lower anxiety scores, but had no placebo group. Controlled human trials have not shown a significant reduction in cortisol versus placebo; the cortisol-lowering effect attributed to ocimumosides A and B comes from animal studies.
Cognitive function
A single 30-day placebo-controlled trial in 71 healthy adults showed significant improvements versus placebo in reaction time and error rate on attention and short-term-memory tasks. Effects were small and have not been replicated.
Blood sugar regulation
In a 4-week placebo-controlled crossover trial in 40 people with mild type 2 diabetes, holy basil leaf (2.5 g/day) lowered fasting glucose by about 17.6% and postprandial glucose by about 7.3% versus placebo. This is a small, older trial, and holy basil has not been shown to replace standard diabetes treatment. Proposed mechanisms such as carbohydrate-enzyme inhibition come mainly from laboratory work.
Anti-inflammatory and antimicrobial activity (laboratory studies only)
These are laboratory findings, not human outcomes: in test-tube studies eugenol inhibits COX-1 and COX-2 enzymes, and tulsi extracts inhibit the growth of various bacteria. No controlled trials have shown holy basil to reduce inflammation or treat infections in people.
Mechanism of action
HPA axis modulation
Ocimumosides A and B interact with corticosteroid receptors and modulate HPA axis feedback sensitivity, reducing ACTH-stimulated cortisol secretion during stress.
COX and 5-LOX inhibition
Eugenol and ursolic acid inhibit both cyclooxygenase (COX-1 and COX-2) and 5-lipoxygenase pathways, providing dual anti-inflammatory action reducing both prostaglandin and leukotriene production.
Alpha-glucosidase and alpha-amylase inhibition
Holy basil phenolic compounds inhibit intestinal carbohydrate-digesting enzymes, slowing glucose absorption from meals and reducing postprandial glucose spikes.
Clinical trials
Randomized controlled trial of Ocimum tenuiflorum (formerly O. sanctum) extract (300 mg/day) vs placebo in 71 healthy adults for 30 days. Outcomes: reaction time, attention measures, error rate, cognitive flexibility, subjective stress. (Sampath et al. 2015, Indian J Physiol Pharmacol)
71 healthy adults. 30-day intervention.
Between-group improvements versus placebo were significant only for cognitive measures: reaction time and error rate on the Sternberg and Stroop tests, plus P300 latency. Salivary cortisol and State-Trait Anxiety scores improved within the treatment group over time but did not differ significantly from placebo. Effect sizes small; single 30-day trial. Note: holy basil is positioned as an adaptogen with cognitive and stress-reducing applications; evidence base is modest.
Randomized crossover trial of holy basil leaf powder (2.5 g/day) vs placebo in 40 patients with mild non-insulin-dependent diabetes for 4 weeks each. Outcomes: fasting glucose, postprandial glucose, urinary glucose. (Agrawal et al. 1996, Int J Clin Pharmacol Ther)
40 mild T2DM patients.
Fasting glucose reduced ~17.6% and postprandial glucose ~7.3% in tulsi period vs placebo. Urinary glucose also reduced. Modest effects; adjunctive to standard diabetes management. Older trial; modern T2DM care has multiple effective pharmaceutical options.